000276084 001__ 276084
000276084 005__ 20240918103627.0
000276084 0247_ $$2doi$$a10.1093/nop/npad004
000276084 0247_ $$2pmid$$apmid:37188167
000276084 0247_ $$2pmc$$apmc:PMC10180362
000276084 0247_ $$2ISSN$$a2054-2577
000276084 0247_ $$2ISSN$$a2054-2585
000276084 0247_ $$2altmetric$$aaltmetric:141509568
000276084 037__ $$aDKFZ-2023-00990
000276084 041__ $$aEnglish
000276084 082__ $$a610
000276084 1001_ $$aDeng, Maximilian$$b0
000276084 245__ $$aClinical outcome following surgical resection and radiotherapy in adult patients with pleomorphic xanthoastrocytoma as defined by DNA methylation profiling.
000276084 260__ $$aOxford$$bOxford Univ. Press$$c2023
000276084 3367_ $$2DRIVER$$aarticle
000276084 3367_ $$2DataCite$$aOutput Types/Journal article
000276084 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1726648560_16238
000276084 3367_ $$2BibTeX$$aARTICLE
000276084 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000276084 3367_ $$00$$2EndNote$$aJournal Article
000276084 520__ $$aMolecular brain tumor classification using DNA methylation profiling has revealed that the methylation-class of pleomorphic xanthoastrocytoma (mcPXA) comprised a substantial portion of divergent initial diagnoses, which had been established based on histology alone. This study aimed to characterize the survival outcome in patients with mcPXAs-in light of the diverse selected treatment regimes.A retrospective cohort of adult mcPXAs were analyzed in regard to their progression-free survival following surgical resection and postoperative radiotherapy. Radiotherapy treatment plans were correlated with follow-up images to characterize the pattern of relapse. Treatment toxicities and molecular tumor characteristics were further analyzed.Divergent initial histological diagnoses were encountered in 40.7%. There was no significant difference in local progression-free (PFS) and overall survival (OS) following gross total or subtotal resection. Postoperative radiotherapy was completed in 81% (22/27) following surgical intervention. Local PFS was 54.4% (95% CI: 35.3-84.0%) and OS was 81.3% (95% CI: 63.8-100%) after 3 years following postoperative radiotherapy. Initial relapses post-radiotherapy were primarily located in the previous tumor location and/or the planning target volume (PTV) (12/13). All patients in our cohort demonstrated the prognostically favorable pTERT-wildtype mcPXA.Our study demonstrated that adult patients with mcPXAs display a worse progression-free survival compared to the reported WHO grade 2 PXAs. Future matched-pair analyses are required with a non-irradiated cohort to elucidate the benefit of postoperative radiotherapy in adult patients with mcPXAs.
000276084 536__ $$0G:(DE-HGF)POF4-312$$a312 - Funktionelle und strukturelle Genomforschung (POF4-312)$$cPOF4-312$$fPOF IV$$x0
000276084 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000276084 650_7 $$2Other$$aDNA methylation profiling
000276084 650_7 $$2Other$$aPleomorphic xanthoastrocytoma
000276084 650_7 $$2Other$$aglioma
000276084 650_7 $$2Other$$amolecular diagnostics
000276084 650_7 $$2Other$$aradiotherapy
000276084 7001_ $$0P:(DE-He78)8126cfb1cc3fa7fa8fd5c20410c6d863$$aHinz, Felix$$b1$$udkfz
000276084 7001_ $$aHarrabi, Semi$$b2
000276084 7001_ $$0P:(DE-He78)a46a5b2a871859c8e2d63d2f8c666807$$aSturm, Dominik$$b3$$udkfz
000276084 7001_ $$0P:(DE-He78)45440b44791309bd4b7dbb4f73333f9b$$aSill, Martin$$b4$$udkfz
000276084 7001_ $$0P:(DE-He78)8d9c904a6cea14d4c99c78ba46e41f93$$aKorshunov, Andrey$$b5$$udkfz
000276084 7001_ $$aEichkorn, Tanja$$b6
000276084 7001_ $$0P:(DE-He78)c59ff25b48c192ed3fd4ad3a4bc9b9c0$$aHörner-Rieber, Juliane$$b7$$udkfz
000276084 7001_ $$aHerfarth, Klaus$$b8
000276084 7001_ $$aJungk, Christine$$b9
000276084 7001_ $$aUnterberg, Andreas$$b10
000276084 7001_ $$0P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9$$aPfister, Stefan$$b11$$udkfz
000276084 7001_ $$0P:(DE-He78)92e9783ca7025f36ce14e12cd348d2ee$$aWick, Wolfgang$$b12$$udkfz
000276084 7001_ $$0P:(DE-He78)a8a10626a848d31e70cfd96a133cc144$$avon Deimling, Andreas$$b13$$udkfz
000276084 7001_ $$0P:(DE-He78)551bb92841f634070997aa168d818492$$aJones, David$$b14$$udkfz
000276084 7001_ $$0P:(DE-He78)8714da4e45acfa36ce87c291443a9218$$aDebus, Jürgen$$b15$$udkfz
000276084 7001_ $$0P:(DE-He78)a1f4b408b9155beb2a8f7cba4d04fe88$$aSahm, Felix$$b16$$udkfz
000276084 7001_ $$aKönig, Laila$$b17
000276084 773__ $$0PERI:(DE-600)2768945-1$$a10.1093/nop/npad004$$gVol. 10, no. 3, p. 307 - 314$$n3$$p307 - 314$$tNeuro-oncology practice$$v10$$x2054-2577$$y2023
000276084 909CO $$ooai:inrepo02.dkfz.de:276084$$pVDB
000276084 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)8126cfb1cc3fa7fa8fd5c20410c6d863$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000276084 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a46a5b2a871859c8e2d63d2f8c666807$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000276084 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)45440b44791309bd4b7dbb4f73333f9b$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000276084 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)8d9c904a6cea14d4c99c78ba46e41f93$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000276084 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)c59ff25b48c192ed3fd4ad3a4bc9b9c0$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000276084 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9$$aDeutsches Krebsforschungszentrum$$b11$$kDKFZ
000276084 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)92e9783ca7025f36ce14e12cd348d2ee$$aDeutsches Krebsforschungszentrum$$b12$$kDKFZ
000276084 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a8a10626a848d31e70cfd96a133cc144$$aDeutsches Krebsforschungszentrum$$b13$$kDKFZ
000276084 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)551bb92841f634070997aa168d818492$$aDeutsches Krebsforschungszentrum$$b14$$kDKFZ
000276084 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)8714da4e45acfa36ce87c291443a9218$$aDeutsches Krebsforschungszentrum$$b15$$kDKFZ
000276084 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a1f4b408b9155beb2a8f7cba4d04fe88$$aDeutsches Krebsforschungszentrum$$b16$$kDKFZ
000276084 9131_ $$0G:(DE-HGF)POF4-312$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunktionelle und strukturelle Genomforschung$$x0
000276084 9141_ $$y2023
000276084 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-08-23
000276084 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-08-23
000276084 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-08-23
000276084 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-08-23
000276084 915__ $$0StatID:(DE-HGF)0112$$2StatID$$aWoS$$bEmerging Sources Citation Index$$d2023-08-23
000276084 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-08-23
000276084 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bNEURO-ONCOL PRACT : 2022$$d2023-08-23
000276084 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-08-23
000276084 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-08-23
000276084 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2023-08-23
000276084 9201_ $$0I:(DE-He78)B300-20160331$$kB300$$lKKE Neuropathologie$$x0
000276084 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x1
000276084 9201_ $$0I:(DE-He78)B360-20160331$$kB360$$lPädiatrische Gliomforschung$$x2
000276084 9201_ $$0I:(DE-He78)B062-20160331$$kB062$$lB062 Pädiatrische Neuroonkologie$$x3
000276084 9201_ $$0I:(DE-He78)E050-20160331$$kE050$$lE050 KKE Strahlentherapie$$x4
000276084 9201_ $$0I:(DE-He78)B320-20160331$$kB320$$lKKE Neuroonkologie$$x5
000276084 980__ $$ajournal
000276084 980__ $$aVDB
000276084 980__ $$aI:(DE-He78)B300-20160331
000276084 980__ $$aI:(DE-He78)HD01-20160331
000276084 980__ $$aI:(DE-He78)B360-20160331
000276084 980__ $$aI:(DE-He78)B062-20160331
000276084 980__ $$aI:(DE-He78)E050-20160331
000276084 980__ $$aI:(DE-He78)B320-20160331
000276084 980__ $$aUNRESTRICTED